The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Milev, P., Ho, B.-C., Arndt, S., & Andreasen, N. C. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.495 · Cited by 920
Persistent Negative Symptoms in Schizophrenia: An Overview
Buchanan, R. W. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl057 · Cited by 443
Kiss, B., Horváth, A., Némethy, Z., Schmidt, É., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160432 · Cited by 367
Self-citationDopamine D3 receptor antagonists as therapeutic agents
Joyce, J. N., & Millan, M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03491-4 · Cited by 237
Treatment of Negative Symptoms in Schizophrenia with Amisulpride
Boyer, P., Lecrubier, Y., Puech, A. J., Dewailly, J., & Aubin, F. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.1.68 · Cited by 229
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Loo, H., Poirier-Littre, M.-F., Theron, M., Rein, W., & Fleurot, O. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.1.18 · Cited by 195
Improvement of Schizophrenic Patients With Primary Negative Symptoms Treated With Amisulpride
Danion, J.-M., Rein, W., Fleurot, O., & the Amisulpride Study Group (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.610 · Cited by 185
Gyertyán, I., Kiss, B., Sághy, K., Laszy, J., Szabó, G., Szabados, T., Gémesi, L. I., Pásztor, G., Zájer-Balázs, M., Kapás, M., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.002 · Cited by 152
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
Martinot, M. P., Lecrubier, Y., Martinot, J., & Aubin, F. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.130 · Cited by 142
Cited by
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Negative symptoms of schizophrenia: new developments and unanswered research questions
Galderisi, S., Mucci, A., Buchanan, R. W., & Arango, C. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30050-6 · Cited by 555
Smith, R. C., Leucht, S., & Davis, J. M. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5133-z · Cited by 41
Negative symptoms, striatal dopamine and model-free reward decision-making in schizophrenia
Brandl, F., Knolle, F., Avram, M., Leucht, C., Yakushev, I., Priller, J., Leucht, S., Ziegler, S., Wunderlich, K., & Sorg, C. (2023) · Brain · doi:10.1093/brain/awac268 · Cited by 24
Czobor, P., Sebe, B., Acsai, K., Barabássy, Á., Laszlovszky, I., Németh, G., Furukawa, T. A., & Leucht, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.816339 · Cited by 20
“Study Design Data were analyzed from a large randomized, doubleblind clinical trial treating patients with schizophrenia with predominantly negative symptoms; the study’s methods and results have been previously published (26).”
BackgroundMethodResultInfluentialSelf-citation
Metadata
- Authors
- Németh, G., Laszlovszky, I., Czobor, P., Szalai, E., Szatmári, B., Harsányi, J., Barabássy, Á., Debelle, M., Durgam, S., Bitter, I., Marder, S., & Fleischhacker, W. W.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 389
- Issue
- 10074
- Pages
- 1103-1113
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2587606972
- Cited by
- 357
- References
- 28
- FWCI
- 22.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)30060-0
- The paper
- Németh, G., Laszlovszky, I., Czobor, P., Szalai, E., Szatmári, B., Harsányi, J., Barabássy, Á., Debelle, M., Durgam, S., Bitter, I., Marder, S., & Fleischhacker, W. W. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)30060-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
